The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.
from Medical Xpress - latest medical and health news stories https://ift.tt/Tkb6MhR
